GABARAPL2

Across TCGA pan-cancer cohorts, GABARAPL2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated GABARAPL2 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GABARAPL2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GABARAPL2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, COAD, and HNSC are the cancer types where GABARAPL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	IV	0.887	0.213	.024	10	view →
COAD	DFS	Median	IV	0.565	1.000	.028	6	view →
HNSC	OS	Quartile	All	0.881	0.587	.015	6	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	6	view →
OV	DFS	Tertile	All	0.816	1.000	.045	4	view →
LSCC	DFS	Median	All	0.985	0.892	.021	3	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

GABARAPL2–CCRCC (DFS)

Open the CCRCC breakdown →